drugset / Trial / NCT04622007
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Timeline
- Start
- 2021-06-02
- Primary completion
- 2024-10-14
- Completion
- 2024-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tomivosertib | Small molecule | 100 mg | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |